Tag: Mash

According to the [FDA](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash), approximately 6% of U.S. adults are affected by MASH, a serious liver disease that can lead to scarring (fibrosis). Recently, major advances have answered the question: **What is the new medication for liver scarring?** by bringing the first-ever medications specifically for this condition to market, offering new hope for treatment.

In a significant medical breakthrough, an injectable form of semaglutide (Wegovy) received U.S. Food and Drug Administration (FDA) approval in August 2025 to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The question, “What is the injection for fatty liver?” now has a definitive answer with the arrival of targeted pharmacological treatments.

Approved by the FDA in March 2024, resmetirom (Rezdiffra) had an initial annual wholesale acquisition cost (WAC) of $47,400. This comprehensive guide will explore **how much does resmetirom cost**, examining the factors that influence its price for patients, including insurance coverage and financial assistance programs.

Rezdiffra (resmetirom) is the first medication approved for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. Understanding what medications should not be taken with Rezdiffra is crucial for preventing potentially harmful drug interactions.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, affects up to one-third of the global population. While there is no single best tablet to treat all forms of fatty liver, the approach often involves lifestyle changes and targeted medication for specific patient groups and disease stages.

With approximately 25-30% of the U.S. population affected by metabolic dysfunction-associated steatotic liver disease (MASLD), the recent FDA approval of the first medication to address this condition marks a significant breakthrough. Rezdiffra (resmetirom) is the new drug to reverse fatty liver damage, specifically targeting the more severe form known as MASH.

In March 2024, Rezdiffra (resmetirom) became the first and only FDA-approved medication for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis. The path to accessing this medication involves specific steps, including a diagnosis from a liver specialist, gaining insurance approval, and navigating a specialty pharmacy network to understand **how can I get Rezdiffra**.

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. What is Rezdiffra, and how does this groundbreaking medication target liver damage to potentially reverse disease progression?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically for metabolic dysfunction–associated steatohepatitis (MASH), a form of fatty liver disease, with moderate to advanced liver scarring. While a promising therapy, it is crucial to understand **what are the side effects of Rezdiffra for fatty liver** to manage treatment effectively and safely.

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved medication specifically for noncirrhotic non-alcoholic steatohepatitis (NASH), now known as MASH. This landmark approval was a significant development for patients and healthcare providers, yet it has raised a critical question: is there a generic for Rezdiffra? The short answer is no, and its status as a brand-name-only medication is tied to complex legal and commercial factors.